palmitoylethanolamide.com.au
HomeResearchLuwen 2023

N-palmitoylethanolamine modulates hippocampal neuroplasticity in rats with stress-induced depressive behavior phenotype

Luwen Zhang, Wenjuan Tang, Yinan Ouyang, Miao Zhang, Ruirui Li, Lianping Sun, Chao Liu, Hailing Yu. Eur J Pharmacol. 2023 Oct 15:957:176041.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Rats exposed to unpredictable chronic mild stress, and HT22 mouse hippocampal cells treated with corticosterone
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
Depression-like behaviour, hippocampal neurogenesis (BrdU, NeuN), synaptic proteins (NCAM, MAP2, SYN, PSD95), and neuronal apoptosis markers, with and without the PPAR-alpha antagonist MK886

What the authors reported

PEA improved the depression-like phenotype, prevented the stress-induced fall in BrdU-positive cells, increased BrdU/NeuN co-localisation and raised synaptic protein levels in the hippocampus. In HT22 cells PEA reduced corticosterone-induced neuron loss, lowered caspase-3 and raised the Bcl-2/Bax ratio. MK886 partly or fully reversed these effects.

Limits of this study

A rat and cell study; it cannot show effect in people. Doses, route, group sizes and treatment length are not in the abstract. The authors declare no competing interests.

Source

PubMed 37673363 · doi:10.1016/j.ejphar.2023.176041

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.